VetMedGuide

Vet Med Guide

Companion animal beside veterinary diagnostic materials.
Diagnostics2026-07-03 · 18 min read

Canine Transitional Cell Carcinoma: BRAF Test, Piroxicam, and Treatment

Canine transitional cell carcinoma (bladder cancer) diagnostics and therapy. CADET BRAF urine test, piroxicam NSAID use, mitoxantrone chemotherapy, survival times, TCO costs, and referral triggers.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Bladder cancer in dogs is a challenging diagnosis for pet owners and primary care veterinarians alike. The most common form of canine bladder cancer is transitional cell carcinoma (TCC)—also frequently termed canine urothelial carcinoma (UC). This highly invasive tumor typically arises in the lower urinary tract, most commonly at the trigone of the bladder, the proximal urethra, and, in male dogs, the prostate.

Because TCC symptoms mimic common urinary tract infections (UTIs) or bladder stones, many dogs are treated with multiple rounds of antibiotics before the underlying tumor is identified. Once diagnosed, managing canine TCC requires a clear understanding of non-invasive diagnostics (such as the urine BRAF mutation test), the limitations of surgery, off-label chemotherapy protocols, staging workflows, and realistic survival expectations.

This guide provides a decision-grade review of the diagnosis, staging, treatment, and prognosis of canine transitional cell carcinoma. It synthesizes decades of clinical trial data and reviews the safety and cost of therapeutic options to help veterinary teams and owners make informed decisions.

Fast answer: What to expect after diagnosis

Canine TCC is rarely cured, but it is highly treatable. The main goal of therapy is to control local tumor growth, prevent urinary tract obstruction, maintain excellent quality of life, and prolong survival time.

  • Primary Symptom Presentation: Hematuria (blood in the urine), stranguria (straining to urinate), pollakiuria (frequent, small urinations), and recurrent urinary tract signs that do not permanently resolve with antibiotics.
  • Non-Invasive Diagnostic Standard: The CADET BRAF urine mutation test. This test detects a specific canine BRAF mutation (V595E) in cells shed in the dog's urine. It has an 85% sensitivity and is nearly 100% specific. A positive test confirms TCC/UC without needing an invasive biopsy.
  • Standard First-Line Treatment: A combination of a nonsteroidal anti-inflammatory drug (NSAID) with anti-tumor activity—specifically piroxicam (0.3 mg/kg orally once daily)—and intravenous chemotherapy, with mitoxantrone (5.0 to 5.5 mg/m² IV every 3 weeks) representing the most common first-line agent.
  • Prognosis & Survival Times: Median survival time (MST) with no treatment is roughly 1 to 2 months. Piroxicam alone extends MST to approximately 6 months. Combining piroxicam with mitoxantrone chemotherapy yields a 35% objective response rate and extends MST to 9 to 10 months (approximately 291 days).
  • High-Risk Breeds: Scottish Terriers (at an estimated 18- to 20-fold relative risk), West Highland White Terriers, Shetland Sheepdogs, Beagles, and Wire Fox Terriers.

For a broader overview of canine cancer options, you can review our mast cell tumor workup and treatment guide, see our overview of hemangiosarcoma in dogs, or read about osteosarcoma in dogs.

What is transitional cell carcinoma and why does it cause urinary signs?

Transitional cell carcinoma is a malignant tumor of the transitional epithelial cells (urothelium) that line the urinary tract. In dogs, TCC is characterized by its highly invasive nature; it routinely invades the muscular wall of the bladder (detrusor muscle) and has a high propensity to spread to regional lymph nodes and distant organs (lungs, spleen, liver, and bone).

Unlike human bladder cancer, which is frequently superficial and associated with smoking, canine TCC is almost always muscle-invasive at the time of diagnosis.

       [Urine Storage]
             │
             ▼
      [Bladder Trigone]  <── Primary Site of TCC (highly invasive)
             │
     ┌───────┴───────┐
     ▼               ▼
[Right Ureter]  [Left Ureter]  <── Obstruction risk (hydronephrosis)
             │
             ▼
         [Urethra]             <── Stenting or bypass may be needed

The Trigone Dilemma

The anatomical location of TCC in dogs is the single biggest driver of its clinical course. Over 90% of cases arise in the trigone area—the funnel-shaped region at the base of the bladder where the ureters enter and the urethra exits.

  1. Obstruction Risk: As the tumor grows, it can physically block one or both ureters, leading to urine backflow into the kidneys (hydronephrosis) and subsequent renal failure. It can also obstruct the urethra, causing complete urinary retention, which is a life-threatening emergency.
  2. Surgical Infeasibility: Because the trigone contains these critical junctions, wide-margin surgical resection is rarely possible. Removing the trigone requires bilateral ureteral reimplantation into another segment of the bladder or bowel—procedures associated with extremely high morbidity and mortality in veterinary patients.

Clinical Signs and Presentation

The tumor causes local inflammation, ulceration, and bleeding, which translates into classic lower urinary tract signs (LUTS). The tissue shedding and bleeding lead to hematuria, while the physical presence of the mass stimulates the stretch receptors in the bladder wall, causing the dog to feel a constant urge to urinate (pollakiuria).

Technicians and owners must monitor these signs closely. When evaluating urinary workups, understanding baseline metrics like the UPC ratio and urinary workup in dogs and cats is important, although a suspected TCC patient will require direct tumor screening rather than simple proteinuria monitoring.

Which dog breeds are at high risk for TCC?

Canine TCC is a classic example of a disease driven by a combination of strong genetic predisposition and environmental triggers. Epidemiology studies, led by researchers at Purdue University (Knapp et al.), have quantified the relative risks among specific breeds.

Breed Predisposition and Relative Risk

  • Scottish Terrier: 18- to 20-fold increased risk compared to mixed-breed dogs. This represents the strongest breed association for any canine cancer.
  • Shetland Sheepdog: 4- to 5-fold increased risk.
  • West Highland White Terrier: 3- to 5-fold increased risk.
  • Beagle: 3- to 4-fold increased risk.
  • Wire Fox Terrier: 3-fold increased risk.

Because of this extreme genetic risk, veterinary oncologists recommend that Scottish Terriers over the age of 6 undergoes routine screening. Screening typically involves annual or semi-annual urinalysis and non-invasive bladder ultrasound.

Environmental Risk Factors

Research has identified several environmental exposures that significantly increase the risk of TCC in genetically predisposed dogs:

  1. Lawn Herbicides and Pesticides: Exposure to phenoxy herbicides (such as 2,4-D) and certain insecticides on lawns is associated with a significantly higher rate of TCC. Predisposed breeds should be kept off recently treated lawns.
  2. Industrial Exposure: Dogs living in industrial areas or near chemical plants show elevated rates of bladder cancer.
  3. Cyclophosphamide Exposure: Dogs treated with cyclophosphamide (a common chemotherapy drug for lymphoma) can develop sterile hemorrhagic cystitis, which can occasionally progress to TCC due to chronic urothelial irritation.

Conversely, studies have shown that feeding dogs yellow-green leafy vegetables (such as broccoli and carrots) at least three times a week can significantly reduce the risk of developing TCC, even in high-risk breeds.

How is TCC diagnosed: the diagnostic pathway

Diagnosing canine TCC requires distinguishing the tumor from chronic cystitis, polypoid cystitis, or bladder calculi. The diagnostic workup follows a specific sequence.

Recurrent Hematuria/Straining
       │
       ▼
[Antibiotic Course (UTI Rule-Out)] ──> Signs Persist
       │
       ▼
[Abdominal Ultrasound / CADET BRAF Urine Test]
       │
       ├─► Positive BRAF: Diagnosis Confirmed (TCC)
       └─► Negative BRAF + Active Mass: Biopsy / Cytology / Alternative Panel

1. Urinalysis and Cytology

A basic urinalysis often reveals hematuria, proteinuria, and active inflammation. Urinanalysis cytology may identify "atypical epithelial cells." However, transitional epithelial cells can become highly atypical in response to simple chronic inflammation or infection. Therefore, cytologic diagnosis of TCC from a standard urine sediment is notoriously difficult and prone to false positives.

  • Biopsy Seeding Risk: Crucially, performing a fine-needle aspirate (FNA) of a suspected bladder mass through the abdominal wall is strongly discouraged. TCC cells are highly transmissible and can easily seed along the needle tract, resulting in tumor growth in the abdominal muscles or skin.

2. Abdominal Ultrasound

Ultrasound is the primary imaging modality for evaluating the bladder. TCC typically appears as an irregular, broad-based, hyperechoic mass protruding into the bladder lumen, frequently centered at the trigone. It can also present as diffuse bladder wall thickening. Ultrasound allows the clinician to measure tumor dimensions, check for ureteral involvement, and evaluate the regional iliac lymph nodes for enlargement.

3. The CADET BRAF Urine Mutation Test

The introduction of the CADET BRAF test (developed by Breen and Mochizuki in 2015) revolutionized veterinary oncology.

  • Mechanism: The test utilizes a highly sensitive digital PCR assay to detect the V595E mutation in the canine BRAF gene. This mutation is present in approximately 85% of dogs with TCC or prostatic carcinoma.
  • Sample Requirement: The test requires roughly 30 mL of voided urine. Because it detects cell-free DNA, the sample does not need to be sterile, but it must be collected before the tumor is surgically altered or treated with chemotherapy.
  • Accuracy: The test has a sensitivity of 85% and a specificity approaching 100%. A positive BRAF result is considered definitive diagnostic proof of urothelial carcinoma, removing the need for invasive cystoscopy or surgery.
  • Limitations: The test is not validated for cats. Furthermore, about 15% of dogs with TCC are "BRAF-negative" because their tumors are driven by alternative genetic pathways. For these dogs, the CADET BRAF PLUS test (which screens for additional chromosomal aberrations) or a tissue biopsy is required.

4. Cystoscopy and Tissue Biopsy

Cystoscopy (passing a rigid or flexible endoscope into the urethra and bladder) allows direct visualization of the tumor, evaluation of urethral involvement, and collection of tissue biopsies using micro-forceps. Traumatic catheterization (vigorously agitating a catheter against the tumor under ultrasound guidance) is an alternative, less invasive method for obtaining tissue fragments, though it carries a risk of urethral trauma.

Canine TCC metastasis and staging workflow

Before initiating treatment, a full staging workflow is necessary to determine the extent of the disease. Staging helps define the prognosis and identifies potential complications (such as regional lymph node compression or pulmonary metastasis) before they cause clinical deterioration.

  • Thoracic Radiographs (Three Views): Essential to screen for pulmonary metastasis. While TCC primarily spreads locally, hematogenous spread to the lungs occurs in approximately 15% to 20% of cases at the time of initial staging, and up to 50% of cases at the time of death.
  • Abdominal Ultrasound: Used to evaluate the medial iliac and jejunal lymph nodes, which are the primary regional lymphatic drainage sites. It also screens for metastasis to the liver or spleen and monitors the kidneys for signs of hydronephrosis due to ureteral compression.
  • Dual-Phase Contrast CT Scans: Increasingly utilized in veterinary specialty hospitals. A contrast CT of the abdomen and pelvis provides highly detailed anatomical maps of the tumor’s local extension, helping to plan palliative stenting or localized radiation therapy.
  • Bone Scans or Skeletal Radiographs: Indicated if the dog presents with unexplained lameness or bone pain. TCC can metastasize to the vertebrae, ribs, or long bones, causing osteolytic lesions that mimic primary bone tumors.

What are the treatment options for canine TCC?

Because complete surgical excision is rarely possible, treatment for canine TCC is usually medical and multimodal.

1. Piroxicam (NSAID Therapy)

The nonsteroidal anti-inflammatory drug piroxicam (a non-selective COX-1 and COX-2 inhibitor) is the cornerstone of TCC therapy.

  • Mechanism: Urothelial carcinomas overexpress the cyclooxygenase-2 (COX-2) enzyme. Piroxicam exerts both direct anti-tumor effects (by inducing apoptosis and inhibiting tumor angiogenesis) and systemic anti-inflammatory effects.
  • Dosing: Standard dosing is 0.3 mg/kg orally once daily, always administered with food.
  • Adverse Effects: Piroxicam carries a high risk of gastrointestinal ulceration and renal toxicity. Gastrointestinal protectants (like misoprostol or omeprazole) are frequently co-administered. Regular monitoring of renal values (BUN, creatinine) and liver enzymes is mandatory. For class-level safety details on NSAIDs, see our guide on veterinary NSAID adverse-event data.

2. Chemotherapy Protocols

To achieve longer survival times, chemotherapy is combined with piroxicam. The most common protocols include:

  • Mitoxantrone (UTV Protocol): Mitoxantrone is an anthracenedione agent that intercalates into DNA. Dosed at 5.0 to 5.5 mg/m² IV every 3 weeks for 4 to 6 cycles, combined with daily piroxicam. This is the classic first-line protocol, offering an objective response rate (tumor shrinkage of >50%) of 35% and stable disease in another 40-50% of patients.
  • Vinblastine: An alkaloid agent that inhibits microtubule formation. Dosed at 2.0 to 3.0 mg/m² IV every 2 weeks, typically combined with daily piroxicam. A randomized trial showed that adding piroxicam to vinblastine more than doubled the remission rate seen with vinblastine alone (58% partial remission versus 23%), making vinblastine + piroxicam a first-line option at several oncology centers (including the Purdue Bladder Cancer Clinic) as well as an effective rescue protocol when mitoxantrone fails.
  • Carboplatin: A platinum-based agent dosed at 300 mg/m² IV every 3 to 4 weeks, combined with daily piroxicam. A 2015 randomized phase III trial (Allstadt et al.) found that carboplatin + piroxicam was not superior to mitoxantrone + piroxicam — response rate, progression-free interval, and survival were similar between the two arms — while carboplatin carries a higher rate of myelosuppression (neutropenia). Carboplatin is therefore generally reserved as an alternative or rescue option rather than a preferred first-line therapy.
  • Cisplatin and Piroxicam: An older combination protocol that offered high response rates but has been largely phased out due to cisplatin's severe nephrotoxicity in dogs.

3. Molecularly Targeted and Off-Label Options

  • Toceranib Phosphate (Palladia): While Palladia is FDA-approved for mast cell tumors, it is increasingly used off-label for TCC. As a tyrosine kinase inhibitor, it targets VEGFR, PDGFR, and Kit, helping to inhibit tumor angiogenesis. It is particularly useful as a rescue agent when standard cytotoxic chemotherapy has failed.
  • Lapatinib: A dual tyrosine kinase inhibitor targeting EGFR and HER2. While studied in clinical trials, its use is currently limited by drug availability and cost, but it represents an active area of oncology research.

4. Palliative Interventions

If the tumor causes urethral or ureteral obstruction, emergency intervention is required to maintain urine flow:

  • Urethral Stenting: Placement of a self-expanding metallic stent (SEMS) across the obstructed urethra under fluoroscopic guidance. This provides immediate relief from obstruction but carries a high risk of permanent urinary incontinence (occurring in roughly 30% of female dogs and 15% of male dogs).
  • Cystotomy Tube Placement: A surgical bypass catheter placed through the abdominal wall directly into the bladder, allowing the owner to drain urine manually via a valve.

5. Radiation Therapy

Coarse-fractionated or stereotactic body radiation therapy (SBRT) can be used to control local tumor growth and relieve pain. While historically limited by severe side effects (radiation cystitis, colitis, and pelvic tissue fibrosis), modern volumetric modulated arc therapy (VMAT) allows precise targeting of the bladder wall while sparing adjacent pelvic organs, extending survival times.

Realistic prognosis, survival times, and treatment costs

Owners must be counseled on realistic outcomes. While TCC is a serious cancer, many dogs maintain an excellent quality of life for months on appropriate medical management.

Prognosis by Treatment Protocol (Canine TCC)

Treatment Protocol Objective Response Rate Median Progression-Free Interval (PFI) Median Survival Time (MST) Key Study / Citation Reference
No Treatment (Palliative support only) 0% < 30 days 30 - 60 days Purdue Oncology Records
Piroxicam Alone (0.3 mg/kg PO q24h) ~18% ~120 days (~4.3 mo) 180 - 195 days (~6 mo) Knapp et al. (1994) JVIM
Piroxicam + Mitoxantrone (5-5.5 mg/m² IV q3wk) ~35% ~194 days 291 - 300 days (~9.5 mo) Henry et al. (2003) Clin Cancer Res
Piroxicam + Vinblastine (2.0-3.0 mg/m² IV q2wk) ~58% ~199 days ~299 days (~10 mo) Knapp et al. (2016) Bladder Cancer
Piroxicam + Carboplatin (300 mg/m² IV q3-4wk) ~13% PR (phase III) ~74 days (phase III) ~161 days (earlier salvage cohort); no survival advantage over mitoxantrone in phase III Allstadt et al. (2015) JVIM Phase III

Total Cost of Ownership (TCO) for TCC Management

Managing canine TCC is financially significant. The table below outlines realistic cost ranges for a 20 kg dog undergoing standard workup and treatment in a veterinary specialty setting:

  • Initial Workup & Diagnosis: $1,200 – $2,200 (Includes abdominal ultrasound, urinalysis, bloodwork, and CADET BRAF test).
  • Chemotherapy (Mitoxantrone, 4-6 cycles): $3,500 – $5,500 (Includes drug cost, catheter placement, professional administration, and post-chemo CBC monitoring).
  • Ongoing Piroxicam + Monitoring: $80 – $150 per month (Includes piroxicam prescription and regular bloodwork to check kidney and liver function).
  • Palliative Urethral Stent (if obstructed): $3,500 – $5,000 (Includes stent, fluoroscopy suite time, and anesthesia).

For a complete breakdown of cancer expenses, see how much dog cancer treatment costs.

When to Refer to a Veterinary Oncologist

Veterinary teams should discuss oncology referral early in the diagnostic process. Triggers for referral include:

  • Confirming a positive urine BRAF result in a high-risk breed.
  • A suspected bladder mass on ultrasound, to plan staging (chest radiographs, lymph node evaluation) without accidental tumor seeding.
  • Initiating chemotherapy (mitoxantrone or carboplatin) safely using specialized closed system transfer devices (CSTDs) and professional administration protocols.
  • Rapidly progressing urinary tract obstruction that may require stenting or palliative radiation.

For details on managing the referral timeline, see when to refer a cancer case to a veterinary oncologist.

FAQs

Is the BRAF urine test accurate for dogs with TCC, and does a negative test rule it out?

The CADET BRAF test is highly accurate, with a specificity of nearly 100% (meaning a positive result is a definitive diagnosis). However, its sensitivity is approximately 85%. This means that roughly 15% of dogs with TCC are "false negatives" because their tumor does not carry the V595E BRAF mutation. If a dog has a visible bladder mass on ultrasound but tests negative on the BRAF test, further screening with the CADET BRAF PLUS panel or a tissue biopsy is required.

Can a dog be cured of bladder cancer with surgery?

Rarely. Because canine TCC almost always develops at the trigone of the bladder, wide surgical margins cannot be achieved without removing the ureters and urethra. Surgery is occasionally attempted if the tumor is located at the apex (dome) of the bladder, far from the trigone. Even in these cases, local recurrence rates are high due to "field cancerization," where the entire urothelium is predisposed to tumor development.

How long can a dog live on piroxicam alone versus piroxicam plus chemotherapy?

A dog treated with piroxicam alone has a median survival time of approximately 6 months (180 days). Combining piroxicam with standard chemotherapy, such as mitoxantrone, increases the median survival time to approximately 9.5 to 10 months (290 to 300 days), with some dogs surviving over a year.

Why are Scottish Terriers so prone to bladder cancer?

Scottish Terriers have a strong genetic predisposition to TCC, carrying an 18- to 20-fold increased risk compared to mixed-breed dogs. This susceptibility is linked to specific inherited genetic markers and an increased sensitivity to environmental chemicals, such as lawn herbicides and pesticides, which accumulate in their urine and cause chronic irritation to the urothelium.

Sources

Topics
OncologyUrologyDrug Safety & Toxicology
Related Articles